AstraZeneca announces option of BRILINTA tablets in the U.S http://www.zithromaxenlinea.com click here . BRILINTA received acceptance from the U.S. Food & Medication Administration on July 20, 2011, and is certainly indicated to lessen the price of thrombotic cardiovascular events in individuals with severe coronary syndrome . BRILINTA has been proven to reduce the price of a mixed end stage of CV loss of life, MI, or stroke in comparison to clopidogrel. The difference between treatments was driven by CV MI and loss of life without difference in stroke. In sufferers treated with an artery-opening procedure referred to as percutaneous coronary intervention , BRILINTA reduces the price of stent thrombosis.